Design Therapeutics, Inc. (NASDAQ:DSGN – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $17.86.
DSGN has been the subject of a number of recent research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Design Therapeutics in a research report on Thursday, October 15th. Wells Fargo & Company assumed coverage on shares of Design Therapeutics in a report on Friday, October 2nd. They issued an “overweight” rating and a $26.00 price objective on the stock.
Get Our Latest Analysis on Design Therapeutics
Hedge Funds Weigh In On Design Therapeutics
A number of large investors have recently modified their holdings of the business. J. Goldman & Co LP bought a new position in shares of Design Therapeutics in the 2nd quarter valued at about $2,558,000. Bank of New York Mellon Corp acquired a new stake in shares of Design Therapeutics in the second quarter valued at about $1,332,000. Frazier Life Sciences Management L.P. bought a new stake in Design Therapeutics during the second quarter worth about $26,189,000. Dimensional Fund Advisors LP raised its holdings in Design Therapeutics by 45.0% during the first quarter. Dimensional Fund Advisors LP now owns 431,840 shares of the company’s stock worth $4,593,000 after acquiring an additional 133,919 shares in the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Design Therapeutics by 42.2% during the 1st quarter. Renaissance Technologies LLC now owns 408,200 shares of the company’s stock worth $4,343,000 after purchasing an additional 121,100 shares during the last quarter. 56.64% of the stock is currently owned by institutional investors and hedge funds.
Design Therapeutics Price Performance
DSGN opened at $10.24 on Friday. The company has a market capitalization of $640.84 million, a price-to-earnings ratio of -8.68 and a beta of 1.68. The business’s 50-day moving average price is $13.12 and its two-hundred day moving average price is $12.95. Design Therapeutics has a 1 year low of $5.70 and a 1 year high of $17.25.
Design Therapeutics (NASDAQ:DSGN – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.02. Sell-side analysts anticipate that Design Therapeutics will post -1.41 earnings per share for the current fiscal year.
Design Therapeutics Company Profile
Design Therapeutics, Inc (NASDAQ: DSGN) is a clinical-stage biotechnology company developing small-molecule medicines for genetic diseases caused by nucleotide repeat expansions. The company’s GeneTAC, or gene-targeted activation compound, platform is designed to reactivate genes that have been silenced by these repeat expansions, with the goal of restoring production of beneficial proteins.
The company’s research has focused on disorders affecting the nervous system, muscles and eyes.
Featured Articles
- Five stocks we like better than Design Therapeutics
- Bloom Energy Just Reported—Its Biggest Order Is Still Waiting on a Pipeline
- Why Western Digital’s AI Storage Boom Defies the Chip Sell-Off
- Grand Canyon Education Strengthens Its Outlook, But Wall Street Remains Divided
- Amex Stock Slides on Job Cuts, But the Real Story Is Macro
Receive News & Ratings for Design Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
